What is sickle cell anemia?

What is Sickle Cell Anemia

Sickle cell anemia is a serious inherited blood disorder caused by a single genetic mutation in the beta-globin gene that produces abnormal hemoglobin (HbS), leading to chronic hemolytic anemia, painful vaso-occlusive crises, and progressive multiorgan damage. 1

Genetic Basis and Pathophysiology

The fundamental defect in sickle cell anemia involves a specific genetic mutation:

• A single nucleotide substitution (C to A) at codon 6 of the beta-globin gene replaces glutamic acid with valine, creating abnormal hemoglobin S (HbS, α2βs2) 1
• When deoxygenated, HbS molecules polymerize and form long chains, causing red blood cells to deform into the characteristic rigid sickle or crescent shape 1, 2
• This sickling process is reversible with reoxygenation, creating continuous cycles of sickling and unsickling as red cells circulate 1
• Prolonged deoxygenation leads to extensive polymerization, irreversible red cell membrane damage, and hemolysis 1

Disease Forms and Severity

Sickle cell disease encompasses several genotypes with varying severity 1:

• Sickle cell anemia (HbSS): The most severe form, representing 50-60% of UK cases, with hemoglobin levels typically 60-90 g/L 1
• HbSβ0-thalassemia and HbSD: Also associated with severe disease and early painful crises 1
• HbSC disease: Moderate severity (25-30% of cases) with higher baseline hemoglobin but increased risk requiring exchange transfusion 1
• HbSβ+ thalassemia: Milder phenotype (5-10% of cases) 1

Fetal hemoglobin (HbF) levels above 8% provide protection by reducing HbS polymerization, resulting in milder symptoms 1

Core Clinical Features

Chronic Manifestations

The disease is characterized by three primary pathologic processes 1:

• Chronic hemolytic anemia: Continuous red cell destruction leading to baseline anemia (hemoglobin 60-90 g/L in HbSS) 1
• Painful vaso-occlusive crises: Recurrent episodes of severe acute pain from sickled cells blocking small blood vessels, causing tissue ischemia 1, 2
• Progressive end-organ damage: Cumulative injury to multiple organs from repeated ischemia-reperfusion cycles 1

Acute Complications

Life-threatening acute events include 1:

• Acute chest syndrome: Respiratory distress requiring urgent evaluation and potential exchange transfusion
• Stroke: Presenting with hemiparesis, aphasia, seizures, or altered consciousness
• Splenic sequestration: Acute splenomegaly with severe anemia
• Aplastic crisis: Typically from parvovirus B19 infection, causing profound anemia with reticulocytopenia below 1%
• Priapism: Prolonged painful erection, particularly concerning if lasting >4 hours due to risk of irreversible tissue damage

Chronic Organ Damage

Long-term complications affecting quality of life and mortality include 1:

• Vascular endothelial damage causing stroke, pulmonary hypertension, and priapism
• Avascular necrosis of hips and shoulders
• Proliferative retinopathy with risk of retinal detachment
• Nephropathy and chronic kidney disease
• Chronic pain syndromes
• Neuropsychological impairment even without overt stroke
• Increased susceptibility to infections from splenic dysfunction

Epidemiology and Demographics

Sickle cell disease affects specific populations globally 1:

• Diagnosed in more than 1:2000 live births in England annually (up to 1:300 in some cities) 1
• Approximately 300,000 infants born worldwide annually with SCD 2
• In the UK: ~14,000 patients with sickle cell disease; 98% are of African or Caribbean background 1
• Also prevalent in families from the Middle East, India, Mediterranean, and South Asian regions 1, 3
• In the US: approximately 100,000 individuals affected 2

Prognosis and Modern Management

With contemporary multidisciplinary care 1:

• Death in childhood is now uncommon in the UK (1-2%) due to newborn screening and early intervention 1
• Survival to the 7th decade is achievable with optimal specialist care 1
• However, life expectancy remains approximately 20 years shorter than the general population 2
• Higher mortality occurs during transition from pediatric to adult healthcare systems 2

Important Clinical Distinctions

Sickle cell trait (HbAS) is fundamentally different from sickle cell disease 1:

• The heterozygous carrier state is mostly benign
• Only becomes clinically relevant at extremes of physiology (e.g., severe sepsis)
• Does not cause the chronic complications of sickle cell disease
• Approximately 240,000 healthy carriers exist in the UK 1